Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

Naveen Pemmaraju, Hagop Kantarjian, Kendra Sweet, Eunice Wang, Jayastu Senapati, Nathaniel R. Wilson, Marina Konopleva, Arthur E. Frankel, Vikas Gupta, Ruben Mesa, Matthew Ulrickson, Edward Gorak, Sumeet Bhatia, Tulin Budak-Alpdogan, James Mason, Maria Teresa Garcia-Romero, Norma Lopez-Santiago, Gabriela Cesarman-Maus, Pankit Vachhani, Sangmin Lee, Vijaya Raj Bhatt, William Blum, Roland B. Walter, Dale Bixby, Ivana Gojo, Madeleine Duvic, Raajit K. Rampal, Marcos de Lima, James Foran, Amir T. Fathi, Aric Cameron Hall, Meagan A. Jacoby, Jeffrey Lancet, Gabriel Mannis, Anthony S. Stein, Alice Mims, David Rizzieri, Rebecca Olin, Alexander Perl, Gary Schiller, Paul Shami, Richard M. Stone, Stephen Strickland, Matthew J. Wieduwilt, Naval Daver, Farhad Ravandi, Sumithira Vasu, Monica Guzman, Gail J. Roboz, Joseph Khoury, Muzaffar Qazilbash, Phyu P. Aung, Branko Cuglievan, Yazan Madanat, Mohamed A. Kharfan-Dabaja, Anna Pawlowska, Justin Taylor, Martin Tallman, Prajwal Dhakal, Andrew A. Lane

Blood (2023) 141 (6): 567–578.

https://doi.org/10.1182/blood.2022017865

Published: 2023

Journal Articles

How thinly can one slice the AML diagnostic pie?

Gary Schiller

Blood (2022) 140 (12): 1330–1331.

https://doi.org/10.1182/blood.2022017653

Published: 2022

Journal Articles

A slow-go prognosis for older patients with newly diagnosed AML

Gary Schiller

Blood (2021) 138 (7): 501–502.

https://doi.org/10.1182/blood.2021012456

Published: 2021

Journal Articles

Investigating Efficacy, Safety, and Biomarkers in a Phase 2 Trial of Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Following Second-Line Lenalidomide-Based Therapy (Tx) in Relapsed or Refractory Multiple Myeloma (RRMM)

David S Siegel, Gary Schiller, Kevin Song, Richy Agajanian, Keith Stockerl-Goldstein, Hakan Kaya, Michael Sebag, Frederic J Reu, Jorge Mouro, Michael Sturniolo, Shankar Srinivasan, Anjan Thakurta, Yasir Nagarwala, Nizar J Bahlis, MD

Blood (2015) 126 (23): 1853.

https://doi.org/10.1182/blood.V126.23.1853.1853

Published: 2015

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation Following Anti-CD19 BiTE ® Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)

Anthony Stein, Max S. Topp, Nicola Goekbuget, Ralf C. Bargou, Hervé Dombret, Adele K. Fielding, Richard A. Larson, Alessandro Rambaldi, Gary Schiller, MD, Gerhard Zugmaier, Catherine Jia, Tapan Maniar, Birgit Huber, Dirk Nagorsen, Hagop Kantarjian, Stephen J. Forman

Blood (2014) 124 (21): 965.

https://doi.org/10.1182/blood.V124.21.965.965

Published: 2014

Journal Articles

Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR)

Blood (2014) 124 (21): LBA-6.

https://doi.org/10.1182/blood.V124.21.LBA-6.LBA-6

Published: 2014

Journal Articles

Initial Results from the Northstar Study (HGB-204): A Phase 1/2 Study of Gene Therapy for β-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex Vivo with a Lentiviral β Α-T87Q -Globin Vector (LentiGlobin BB305 Drug Product)

Alexis A. Thompson, MD, John E Rasko, MBBS, PhD, Suradej Hongeng, MD, Janet L. Kwiatkowski, MD MSCE, Gary Schiller, MD, Christof von Kalle, MD, Marina Cavazzana, MD PhD, Philippe Leboulch, MD, Alexandria Petrusich, Sandeep Soni, MD, Mark C. Walters, MD

Blood (2014) 124 (21): 549.

https://doi.org/10.1182/blood.V124.21.549.549

Published: 2014

Journal Articles

Results Of a Phase 2 Randomized, Open-Label, Study Of Lower Doses Of Quizartinib (AC220; ASP2689) In Subjects With FLT3-ITD Positive Relapsed Or Refractory Acute Myeloid Leukemia (AML)

Jorge E. Cortes, MD, Martin S Tallman, MD, Gary Schiller, MD, Denise Trone, Guy Gammon, MD, Stuart Goldberg, MD, Alexander E Perl, MD, Jean-Pierre Marie, MD, Giovanni Martinelli, Mark Levis, MD, PhD

Blood (2013) 122 (21): 494.

https://doi.org/10.1182/blood.V122.21.494.494

Published: 2013

Journal Articles

Phase 3 Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin Lymphoma (EXTEND): End of Study Results.

Ruth Pettengell, FRACP, PhD, Pier Luigi Zinzani, MD, PhD, Geetha Narayanan, MD, Fernando Hurtado de Mendoza, MD, Raghunadharao Digumarti, MD, Henry Gomez, MD, Bertrand Coiffier, MD, PhD, Gary Schiller, MD, David A. Rizzieri, MD, Paul Cernohous, MS, Lixia Wang, PhD, Jack Singer, MD

Blood (2010) 116 (21): 2833.

https://doi.org/10.1182/blood.V116.21.2833.2833

Published: 2010

Journal Articles

A Phase 1b Study of Midostaurin (PKC412) in Combination with Daunorubicin and Cytarabine Induction and High-Dose Cytarabine Consolidation in Patients Under Age 61 with Newly Diagnosed De Novo Acute Myeloid Leukemia: Overall Survival of Patients Whose Blasts Have FLT3 Mutations Is Similar to Those with Wild-Type FLT3.

Richard M Stone, MD, Thomas Fischer, MD, Ronald Paquette, MD, Gary Schiller, MD, Charles A. Schiffer, MD, Gerhard Ehninger, MD, Jorge Cortes, MD, Hagop M. Kantarjian, MD, Daniel J. DeAngelo, MD, PhD, Alice Huntsman-Labed, Catherine Dutreix, MD, Sumita Rai, MD, Frank Giles, MD

Blood (2009) 114 (22): 634.

https://doi.org/10.1182/blood.V114.22.634.634

Published: 2009

Journal Articles

Pivotal Phase 2 Study of Weekly Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®) in Adults with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Progressing Following Two Anti-leukemia Treatment Lines.

Susan O'Brien, MD, Gary Schiller, Lloyd E. Damon, MD, John Lister, MD, Farhad Ravandi, MD, Dan Douer, MD, Aisha Masood, MD, Dina Ben-Yehuda, Jacob M. Rowe, MD, Nicola Gökbuget, Walter Aulitzky, Wendy Stock, MD, Steven Coutre, MD, Leonard Heffner, MD, Melissa L. Larson, MD, Karen Seiter, MD, Anne E Hagey, MD, Steven R. Deitcher, MD, Hagop M. Kantarjian, MD

Blood (2009) 114 (22): 3088.

https://doi.org/10.1182/blood.V114.22.3088.3088

Published: 2009

Journal Articles

Survival after Complete Response to Treatment with Laromustine (CLORETAZINE ® ) in Elderly Patients with De Novo Poor Risk Acute Myelogenous Leukemia (AML).

Susan O’Brien, M.D., Gary Schiller, Robert Kenneth Stuart, MD, Diana Hudak, Francis Giles, MD

Blood (2008) 112 (11): 940.

https://doi.org/10.1182/blood.V112.11.940.940

Published: 2008

Journal Articles

Early Signs of Tolerability and Activity in a Phase 2 Study of Weekly Vincristine Sulfate Liposomal Injection (VSLI, MarqiboÒ) in Adults with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Progressing Following Two Anti-Leukemia Treatment Lines

Susan O’Brien, M.D., Lloyd E. Damon, MD, Melissa L. Larson, MD, Gary Schiller, Wendy Stock, MD, Deborah A Thomas, MD, Biao Lu, Michael S. Imperiale, MD, Hagop M Kantarjian

Blood (2008) 112 (11): 3959.

https://doi.org/10.1182/blood.V112.11.3959.3959

Published: 2008

Journal Articles

Updated Results of a Phase I/II Trial of Autologous Peripheral Blood Progenitor Cell Transplantation with Velcade ™ Maintenance as Treatment for Intermediate- and Advanced-Stage Multiple Myeloma

Mickey Liao, MD, R Malone, K Bartoni, B Habtemariam, Ronald Paquette, Sven de Vos, Mary C Territo, Gary Schiller

Blood (2008) 112 (11): 3710.

https://doi.org/10.1182/blood.V112.11.3710.3710

Published: 2008

Journal Articles

Combination of Vorinostat Plus Bortezomib for the Treatment of Patients with Multiple Myeloma Who Have Previously Received Bortezomib

Donna M. Weber, Sundar Jagannath, MD, Ronald Sobecks, Gary Schiller, Lisa Chiacchierini, David Reiser, Carol Oerth, Jose Garcia-Vargas, Syed Rizvi

Blood (2008) 112 (11): 3711.

https://doi.org/10.1182/blood.V112.11.3711.3711

Published: 2008

Journal Articles

Inhibition of the Akt Pathway in MM Cell Lines by the Anti-TfR-IgG3-Avidin Fusion Protein (Anti-TfR-IgG3-Av): Role in Chemosensitization to CDDP-Induced Apoptosis

Eriko Suzuki, Ph.D., Kazuo Umezawa, Ph.D., Gustavo Helguera, PhD, Tracy R Daniels, Ph.D., Gary Schiller, James R. Berenson, MD, Manuel L Penichet, M.D., Ph.D., Benjamin Bonavida, PhD

Blood (2008) 112 (11): 4473.

https://doi.org/10.1182/blood.V112.11.4473.4473

Published: 2008

Journal Articles

Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission

Blood (2008) 112 (2): 426–434.

https://doi.org/10.1182/blood-2007-12-128918

Published: 2008

Journal Articles

Graft-Versus-Leukemia Effect Is Equivalent in Recipients of Matched Sibling and Matched Unrelated Donor Conventional Hematopoietic Cell Transplant.

Blood (2007) 110 (11): 3049.

https://doi.org/10.1182/blood.V110.11.3049.3049

Published: 2007

Journal Articles

Phase IB Study of PKC412, an Oral FLT3 Kinase Inhibitor, in Sequential and Simultaneous Combinations with Daunorubicin and Cytarabine (DA) Induction and High-Dose Cytarabine Consolidation in Newly Diagnosed Adult Patients (pts) with Acute Myeloid Leukemia (AML) under Age 61.

Richard M. Stone, MD, Thomas Fischer, MD, Ronald Paquette, MD, Gary Schiller, MD, Charles A. Schiffer, MD, Gerhard Ehninger, MD, Jorge Cortes, MD, Hagop Kantarjian, MD, Daniel A. DeAngelo, MD, PhD, Georgio Massimini, MD, Xiaoming Li, PhD, Penny Phillips, PhD, Francis Giles, MD

Blood (2006) 108 (11): 157.

https://doi.org/10.1182/blood.V108.11.157.157

Published: 2006

Journal Articles

Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor

Patrick P. Ng, Gustavo Helguera, Tracy R. Daniels, Simon Z. Lomas, Jose A. Rodriguez, Gary Schiller, Benjamin Bonavida, Sherie L. Morrison, Manuel L. Penichet

Blood (2006) 108 (8): 2745–2754.

https://doi.org/10.1182/blood-2006-04-020263

Published: 2006

Includes: Supplemental data

NARROW

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

How thinly can one slice the AML diagnostic pie?

A slow-go prognosis for older patients with newly diagnosed AML

Investigating Efficacy, Safety, and Biomarkers in a Phase 2 Trial of Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Following Second-Line Lenalidomide-Based Therapy (Tx) in Relapsed or Refractory Multiple Myeloma (RRMM)

Allogeneic Hematopoietic Stem Cell Transplantation Following Anti-CD19 BiTE ® Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)

Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR)

Initial Results from the Northstar Study (HGB-204): A Phase 1/2 Study of Gene Therapy for β-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex Vivo with a Lentiviral β Α-T87Q -Globin Vector (LentiGlobin BB305 Drug Product)

Results Of a Phase 2 Randomized, Open-Label, Study Of Lower Doses Of Quizartinib (AC220; ASP2689) In Subjects With FLT3-ITD Positive Relapsed Or Refractory Acute Myeloid Leukemia (AML)

Phase 3 Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin Lymphoma (EXTEND): End of Study Results.

Pivotal Phase 2 Study of Weekly Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®) in Adults with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Progressing Following Two Anti-leukemia Treatment Lines.

Survival after Complete Response to Treatment with Laromustine (CLORETAZINE ® ) in Elderly Patients with De Novo Poor Risk Acute Myelogenous Leukemia (AML).

Early Signs of Tolerability and Activity in a Phase 2 Study of Weekly Vincristine Sulfate Liposomal Injection (VSLI, MarqiboÒ) in Adults with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Progressing Following Two Anti-Leukemia Treatment Lines

Updated Results of a Phase I/II Trial of Autologous Peripheral Blood Progenitor Cell Transplantation with Velcade ™ Maintenance as Treatment for Intermediate- and Advanced-Stage Multiple Myeloma

Combination of Vorinostat Plus Bortezomib for the Treatment of Patients with Multiple Myeloma Who Have Previously Received Bortezomib

Inhibition of the Akt Pathway in MM Cell Lines by the Anti-TfR-IgG3-Avidin Fusion Protein (Anti-TfR-IgG3-Av): Role in Chemosensitization to CDDP-Induced Apoptosis

Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission

Graft-Versus-Leukemia Effect Is Equivalent in Recipients of Matched Sibling and Matched Unrelated Donor Conventional Hematopoietic Cell Transplant.

Phase IB Study of PKC412, an Oral FLT3 Kinase Inhibitor, in Sequential and Simultaneous Combinations with Daunorubicin and Cytarabine (DA) Induction and High-Dose Cytarabine Consolidation in Newly Diagnosed Adult Patients (pts) with Acute Myeloid Leukemia (AML) under Age 61.

Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only